Tenderwize
Zurück zur Suche

Open-house rebate agreement for Roxithromycin

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Mar 31, 2027 · 218 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Roxithromycin, ATC J01FA06

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

58 / 100

Risikofaktoren

The notice requires original submission and states that electronic submission is not allowed, which increases the risk...

Only authorised and marketable medicinal products in Germany are eligible, and additional AMIce/Lauer-Taxe evidence may...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Non-exclusive open-house rebate agreements for pharmaceutical products containing Roxithromycin (ATC J01FA06).
  • Supply of authorised and marketable medicinal products in Germany under uniform contract conditions.
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for Roxithromycin (ATC J01FA06) pharmaceutical products by AOK Rheinland-Pfalz/Saarland. The notice states that interested pharmaceutical companies may join on equal terms, with no individual negotiations and no selection decision. The contract period runs from 01.06.2025 to 31.05.2027, with monthly entry possible, but the first submission deadline for the initial start date was 30.04.2025. No contract value is stated. The procedure is explicitly described as not constituting a public procurement contract under the procurement rules, although it is published in TED for transparency.

Risiken

The notice requires original submission and states that electronic submission is not allowed, which increases the risk...

Only authorised and marketable medicinal products in Germany are eligible, and additional AMIce/Lauer-Taxe evidence may...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Only authorised and marketable medicinal products in Germany may be supplied.

Administrative

  • If a product is not listed in Lauer-Taxe at submission time, an AMIce public extract must be provided.
  • The AMIce extract must show product name, marketing authorisation holder or authorised manufacturer, dosage form, active substance, and marketability.

Auftraggeber

Lose (1)

LOT-0001

Open-house rebate agreement for Roxithromycin

Single lot covering non-exclusive open-house rebate agreements for medicinal products containing Roxithromycin (ATC J01FA06). The scope excludes paediatric medicines listed in the BfArM list under Section 35(5a) SGB V. Contract terms are uniform for all participants; no individual negotiations are conducted. Contracts can start on the first day of a month within the 24-month period, with a maximum duration of 24 months from the earliest start date. The lot information is explicit in the structured data and notice text.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

May 2025 - May 2027

Kategorie

Pharmaceutical products

Frist

Deadline Mar 31, 2027

Vergabedetails

Veröffentlichungsdatum
10 Apr 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
236088-2025

Dokumente (1)

Ähnliche Ausschreibungen